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Evidence-based medicine (EBM) and personalized medicine (PM) are fashionable concepts 
frequently endorsed by medical and pharmacological journals. Everyone appears to agree that both should 
be implemented in the real world of clinical practice as soon as possible. The author believes that it will 
not be easy to implement both simultaneously since their approaches collide. While the EBM approach 
focuses on using randomized clinical trials (RCTs) to establish the best treatment for the average patient 
and ignores the outliers, PM focuses on the outliers (Table 1). 
To appreciate this, one must reckon with the statistical concept of heterogeneity, which seems 
widely ignored. Feinstein1 (both a physician and a scientist with mathematical training) pointed out that 
statistical heterogeneity is largely overlooked by statistics textbooks.  In the view of the author2 it is not 
surprising that statistical heterogeneity is ignored, in that clinicians have no idea what statistical 
heterogeneity means; they just want their statistician to analyze their data and produce the right answer.  
Secondly, statisticians receiving data from clinicians do not want to raise the possibility that the 
clinician’s data is heterogeneous since then it could not be analyzed with the usual statistical methods or 
at least could not be analyzed collectively.   The author believes that when dealing with drug response, 
EBM assumes that the “reality” of the drug response is statistically homogeneous; thus, an average 
response represents individuals quite well.  PM, on the other hand, assumes that reality is not 
homogeneous since the average response is not representative of a sample of individuals, and drug 
response is a statistically heterogeneous phenomenon (Table 1).   
 How is this misunderstanding possible? Is EBM coming from Mars and PM from Venus? Yes. 
These two concepts have completely different origins; EBM was developed in the context of medical 
education and PM in the context of clinical pharmacology. Moreover, the battle between EBM versus PM 
may just be another skirmish in the larger ongoing wars between those who think medicine is a science 
and those who think it is an art.3,4 The conflict can also be exemplified by other battles such as those 
between defenders of:  1) empirical observation versus mechanistic disease models,5 2) probabilistic and 
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empirical thinking versus deterministic and explanatory thinking,6 3) evaluation of interventions versus 
discovery and explanation,7  and 4) public health versus individual patient health. 8,9 
This article briefly describes: 1) the history of EBM, 2) the recent realization that statistical 
heterogeneity may be an obstacle in EBM’s attempts to summarize medical practice, 3) the history of PM, 
4) the author’s opinion that the level of heterogeneity or the lack thereof is that which dictates whether or 
not PM can easily coexist with EBM, 5) the history of attempts to explore drug response heterogeneity in 
psychiatry, and 6) proposed next steps for moving beyond this stalemate between EBM and PM. 
History of EBM 
 The developers of EBM, Sackett and coworkers,10 proposed that EBM had its origins in the first 
attempts to use statistics in clinical practice in 19th century France. EBM has been compared in particular 
to the “Medical Observation” developed by Pierre Charles Alexandre Louis in Paris during the 1830s and 
1840s, who crusaded against the use of bloodletting in pulmonary infections, using the observational 
method and numerical calculations.5,11 Gerber and coworkers12 argued that EBM is fundamentally 
different from the mere attempts to introduce statistics in medicine in 19th century France, since its 
fundamental innovation is that EBM relies on and enhances a more equal relationship between physicians 
rather than the historical tradition of relying on experts. This appears to agree with one of Sackett’s lesser 
known articles13 in which he stressed that, when compared with the traditional method of educating 
physicians, EBM “puts a much lower value on authority”. 
In spite of these disagreements about antecedents, everyone agrees that EBM was mainly 
developed at McMaster University in Canada in the 1980s and 1990s14-16 by Guyatt and Sackett, among 
others. Sackett contributed to EBM’s dissemination by moving to Oxford University.14 EBM became a 
mainstream concept in medicine after the publication of two articles, one in JAMA16 in 1992 and one in 
the British Medical Journal10 in 1996.  According to Vandenbrucke17, however, the British Medical 
Journal, Annals of Internal Medicine, and JAMA have greatly championed EBM, whereas The Lancet and 
the New England Journal of Medicine have kept some distance. 
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In a recent review updating the progress of EBM, Guyatt and coworkers18 gave credit to Cochrane, 
Sackett and Feinstein for laying its foundations.   They credited the Scottish epidemiologist Archie 
Cochrane for insisting that the clinical disciplines should summarize evidence concerning their 
practices.19 They acknowledged their colleague Sackett for developing the teaching innovations. They 
also credited Feinstein for defining the principles of quantitative clinical reasoning. It is interesting that 
Feinstein was recognized since he was critical of EBM until his death and helped to develop a patient-
centered approach.20  
According to Sackett and Rosenberg,21 the rapid growth of randomized clinical trials, the slow 
pace of updating textbooks, the lack of time physicians have for keeping up with journals, and the lack of 
efficacy of continual medical education in improving clinical competence explains the need for the 
development of EBM. According to Woolf,22 the main historical factor contributing to the introduction of 
EBM was the wild variation in medical practice for the same types of patients, including overuse (and 
sometime underuse) of services leading to increased costs, a major issue for Cochrane.20  Sackett and 
coworkers10 defined EBM as “the conscientious, explicit, and judicious use of current best evidence in 
making decisions about the care of individual patients. The practice of evidence based medicine means 
integrating individual clinical expertise with the best available external clinical evidence from systematic 
research.” Most would agree that the heart of EBM is the reliance on RCTs as the best alternative for 
guiding medical knowledge. 23 More recently, Reilly24 very wisely has acknowledged that EBM is three 
different things: 1) a scientific hypothesis, 2) an ever-evolving body of evidence, and 3) an idealized way 
of practicing medicine.  
In the opinion of this writer, EBM is a definitively a departure from the prior 2,500 years in the 
sense that traditionally the study of medicine was primarily based on mentorship with a more experienced 
physician, ideally somebody who was an “expert”. The traditional approach in learning medicine was that 
of rotating with a mentor who taught the student physician the art of medicine; then the physician 
practiced by himself and acquired experience as he or she made his or her own mistakes (sometimes lethal 
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to the patients) and, in the case of a few, became a physician mentor. Thus, using the traditional way of 
educating physicians, the older the physician, the more wise and experienced he or she was supposed to 
be.26 The EBM approach has inverted this process since older physicians tend to be less experienced with 
the updates provided by the EBM approach.26  
EBM can be seen as the culmination of the introduction of the scientific method in medicine27 
since, during the last 500 years, greater scientific knowledge has progressively been introduced in the 
mentoring of physicians. In the 20th century, the development of the RCT approach and its progressive 
adoption by government drug agencies for marketing drugs has made the knowledge gained from RCT 
available and, more importantly, has led to the combination of available RCT in the so-called meta-
analyses. The realization that RCT and meta-analyses should be the cornerstone for medical decisions and 
medical education has led to EBM. According to Feinstein,27 this new “faith” is expanded mainly by 
epidemiologists, while physicians usually defer to epidemiologists or other experts, since they rarely 
master the “secretive” art of summarizing average drug responses using meta-analytic techniques. The 
believers in EBM rarely recognize a major practical problem:  the RCT which are used to test drug 
efficacy and gain Food and Drug Administration (FDA) approval for marketing usually deal with short-
term drug response in otherwise healthy and uncomplicated patients who are also willing to enter RCT. 
Physicians, however, often deal with chronically ill patients who usually take multiple medications and 
can be uncooperative in taking medications. Thus, physicians are frequently interested in drug response 
after many months or years of treatment in all types of patients.28  More recently, an attempt has been 
made to increase the representativeness of RCT by conducting practical or pragmatic trials29 that focus on 
effectiveness rather than efficacy, but there are very few or no pragmatic clinical trials for most medical 
problems. The author works in an acute hospital for patients with severe mental illness; it has 2,000 
admissions/year and nearly all its patients would be excluded from pragmatic trials due to the risk of 
suicide attempts (half of the patients have previously attempted suicide) and/or the inability/unwillingness 
to sign a complex consent form due to severe cases of psychosis, mania or depression.30 Thus, “current 
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EBM” does not include well-controlled studies for the types of very sick patients treated in his hospital.  
Knotterus and Dinant31 wisely stated that “medicine based evidence is a prerequisite for EBM” and that 
“future research methods must find ways of accommodating clinical reality, not ignoring it”. The sad truth 
is that the more difficult the patient, the less evidence is available to treat him or her.  It is very unlikely 
that RCTs will ever be conducted for the types of patients seen in the author’s hospital since these patients 
combine severe mental illnesses with extensive history of suicidality, high levels of co-morbid substance 
abuse, and high levels of medical co-morbidity.32        
Statistical heterogeneity and EBM 
 Although in 1997 Feinstein and Horwitz33 emphasized the problem of lack of homogeneity in 
RCTs, only recently have statisticians34,35 started focusing on the issue that the average patient may not be 
a good representative of all patients. There is no general agreement on how to best deal with this complex 
problem. The best and most sophisticated way is through stratification,34 separating patients according to 
a characteristic that has a crucial effect on drug response and then randomizing the groups separately. The 
number of RCTs utilizing this courageous approach36 may increase in the future but it is likely to be a 
slow process if the RCTs are designed by drug companies; they may not be interested in taking risks since 
stratification decreases statistical power and therefore may require larger recruitment samples. When 
heterogeneity is not considered a priori and resolved by a design using stratification, it is only possible to 
deal with it a posteriori, using subgroup statistical analyses to test for heterogeneity in treatment effects;35 
which is a rather controversial subject among statisticians. 
 Regarding a posteriori classification, a statistician with long experience in working on industry 
RCTs, Senn37-41 has provided a comprehensive critique on heterogeneity.  He criticizes EBM’s defenders 
by reminding them that RCTs only provides information on averages and that the calculation of an 
average number, such as the number needed to treat, assumes that all patients benefit equally;38,41 and he 
incorporates the thinking from a PM expert in his solutions.42,43 Senn reminds37-41  us that a RCT has three 
main sources of error variability besides the differences between treatments (the average differences 
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between treatments over all randomizations).  They include: 1) between-patient variability (the average 
differences between patients), 2) patient-by-treatment interaction (the extent to which difference between 
treatment differs from one patient to another); and 3) within-patient error (the variability shown from 
treatment period to treatment period when the same patient is given the same treatment).38   Senn says that 
parallel RCTs cannot distinguish between the three types of error variability and cross-over RCTs (in 
which each patient only receives the treatment and control conditions) cannot distinguish between patient-
by- treatment interaction and within-patient error.38  He notes that differences in drug response may 
include genetic variability but genetic variability cannot exceed individual variability shown by patient-
by- treatment interaction in RCTs; 38,41 In addition, the same data cannot be used to test for differences 
between groups in RCTs and then used to classify patients retrospectively.37,41  Senn also points out that 
the assumption that pharmacogenetics is important in drug response is largely untested.41,42  
History of PM 
Physicians have traditionally practiced PM in their attempts to decide the best treatment for each 
of their patients.44 However, they were not using the term “PM” and they were probably basing their 
traditional PM on their subjective preferences or their understanding of what was best for the patient, and 
not on scientific knowledge. The current use of the term “PM” can be explained by advances in clinical 
pharmacology.45-48 Meyer45  has presented the most comprehensive historical review of these 
pharmacological advances; here only a brief overview of how these advances have led to the development 
of PM is presented. At the beginning of the 20th century, around the time the word “genetic” was first 
used, Garrod49 hypothesized that there was a “chemical individuality” and “those idiosyncrasies with 
regard to drug” response may be explained by evolution. In the 1950s45-48 pharmacologists observed that 
some severe adverse drug reactions (ADRs) only occurred in a small number of patients. They included 
hemolytic anemia after the use of primoquine, apnea with succynilcholine, and peripheral neuropathy 
with isoniazid. In 1959, Vogel50 coined the term “pharmacogenetics”. In the 1960s-70s45-48 two 
phenotypes, poor metabolizers and extensive metabolizers, were described for several drugs including 
 8
tricyclic antidepressants (TCAs), debrisoquine, spartein and mephenytoin. In the 1980s-90s,45-48 1) the 
various genes associated with the cytochrome P450 (CYP) isoenzymes were discovered, 2) the allele 
variants associated with poor metabolism were described, 3) the ultrarapid metabolizers were described in 
patients taking TCAs and were associated with a gene duplication or multiplication, and 4) other 
pharmacokinetic genes began to be identified.   
In the late 1990s, advances in genetics allowed parallel genetic testing51 (or testing for multiple 
genes at the same time) through the use of the so-called DNA microarrays. Thus, the new term 
“pharmacogenomics” was coined for the study of all genes that may influence drug response.52 In 1997 
the development of DNA microarray technology led Science53 to define “personalized prescription” as 
“tailoring drugs to a patient’s genetic makeup” and to predict that personalized prescription would “soon” 
reach clinical practice.  The race for the human genome and the political decision in 2000 by President 
Clinton that the race was over54 led to further hype in lay55 and scientific journals56 about the promises of 
genetics to personalize medicine.  The generalized use of personalized prescription would begin in 2015, 
according to Time magazine,55 or 2020, according to JAMA.56 The first decade of the 21st century has led 
to greater acknowledgement of difficulties and complexities at three levels: 1) genetic science, 2) the use 
of genetic DNA microarrays in clinical practice, and 3) the development of other microarrays. The 
complexity of the increasing genetic knowledge led to the realization that the function of approximately 
one-third of human genes is unknown and that duplications and other variants, the so-called copy number 
variations (CNV)  and epigenetics, may influence drug response.57  The introduction of the first DNA 
microarray approved by the Food and Drug Administration (FDA) for pharmacogenetic testing  in 
20069,58  has led to very limited clinical use for reasons that are complex.59 The further development of 
DNA microarray technology has allowed the testing of multiple other products besides DNA, including 
proteins, RNAs, and lipids, and to the development of new diagnostic branches such as “protenomics”, 
“transcriptomics” and “metabonomics”. All of these new techniques called “omics”60 have brought 
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additional expectations about their use in PM and also the rapid realization of the complexities of the 
scientific and practical issues involved in taking these microarrays to clinical practice.61,62   
In the time frame of 3-5 years these technologies, microarrays and genotyping methods continue to 
advance and make prior versions obsolete by becoming more powerful (providing more and more data – 
up to millions of pieces of data) and progressively cheaper. To make these advances more suitable for 
clinical practice, “better” and “cheaper” is important, but advances in making these tests easier to use are 
also crucial. In that sense, the introduction of nanotechnology in genotyping tests may be an important 
step.63  The FDA approved a warfarin pharmacogenetic test using this technology in September 2007.64 
This technology can provide genotyping results in a few hours, providing busy clinicians with rapid 
answers without the need of waiting 1-2 days for the usual genotyping test before starting a new 
medication. 
In the view of the author,62 personalized prescription is the branch of PM focused on 
individualizing drug prescription. To predict drug response, one has to use genetic information in the 
context of environmental and personal factors;65 furthermore, these other factors may be more important 
than genetics in determining drug response with some drugs. Thus, personalized prescription should be 
built around the idea that pharmacology is a mechanistic science. Chemistry (and physics) are 
foundational in understanding pharmacological response but pharmacologists who are familiar with 
pharmacological mechanisms at the cellular, tissue, and organic levels, rather than chemists, are the ones 
who can predict drug response.66 Unfortunately, pharmacokinetic and pharmacodynamic mechanisms 
vary from drug to drug.62 In a view of personalized prescription based on pharmacological mechanisms 
one can propose the following: 67,68 1) a drug’s pharmacokinetic and pharmacodynamic mechanisms are 
behind its efficacy and safety; 2) genetic, environmental and personal variables influence drug 
pharmacokinetic and pharmacodynamic mechanisms and through them its efficacy and safety; 3) 
personalizing drug selection is much more complex than personalizing drug dosing; 4)  in the process of 
personalizing drug selection, eliminating a drug in the process is easier than choosing a drug;  5) 
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personalizing dosing is easier when the drug follows linear kinetics and has a narrow therapeutic window; 
and 6) personalizing dosing in wide-therapeutic-window drugs may not make practical sense since 
physicians may be very arbitrary in their selection of drug dosages.  
Statistical heterogeneity or lack of homogeneity and PM  
 The crucial role of the level of statistical heterogeneity in PM and its implications related to the 
statistical power of the studies has not been addressed by the literature. The first question regards 
personalizing prescription for a specific drug response.   Is it completely heterogeneous (each patient 
responds differently)?  Is it somewhat heterogeneous?  Is it homogeneous (most patients respond similarly 
to the drug)?  Thus, knowing the statistical distribution of drug response is absolutely crucial in the design 
of PM studies. If drug response is absolutely heterogeneous (it lacks homogeneity) and cannot be 
extrapolated from individual to individual, it is impossible to study or predict unless we focus on the prior 
response of the same drug in the same patient. As pharmacokinetic and pharmacodynamic mechanisms 
are fairly similar across all humans, probably due to the effects of individual selection associated with 
evolution, drugs with non-homogeneous response do not appear to exist. Thus, patients appear to be 
relatively homogeneous in drug response, with differing levels of heterogeneity.  However, heterogeneity 
varies from drug to drug due to the peculiarities of variations in pharmacokinetic and pharmacodynamic 
mechanisms. If one wants to defend EBM as being a good representation of drug response, one must 
assume that the mean represents the population well and that the standard statistical test can be properly 
used since the sample shows statistical homogeneity (Table 1). If one wants to defend PM as being a 
better representation of drug response than EBM, one must assume that a good number of subjects are 
outliers and should be excluded from the usual statistical analysis and that mean results do not represent 
them; therefore outliers should be studied separately (Table 1).  
To illustrate, three outlier prevalences in the population are considered in this discussion as 
examples:  <1% of the population; 1-10%, and 50%. If the outliers are so rare as to include <1% of the 
population, they are quite unlucky; it is very unlikely that well-designed studies using RCTs will ever be 
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conducted in them. This is the tragedy of EBM: the more difficult the patient is, the more likely that 
he/she will be ignored by the EBM approach.65 An example may clarify this:  some very unlucky subjects 
do not have CYP2D6 and  CYP2C19. They number approximately 1 per 1000 or fewer in each race.69 If 
you are one of these unusual subjects, it may be better for you not to need an antidepressant since almost 
all of them are mainly metabolized by one of these two enzymes (and frequently the other CYP is used as 
an auxiliary pathway). 70 If you are a pharmacologist interested in antidepressants and are trying to recruit 
50 of these double poor metabolizers for a controlled clinical trial you have the herculean task of needing 
to screen 50,000 patients to identify 50 who meet the study criteria.  
On the other hand, when “unusual” subjects include 50% of the population, such as with gender, 
there may be “too many outliers.” Let’s imagine that one scientist believes males can respond to a new 
drug but most females do not respond. He/she will have the difficult task of convincing a pharmaceutical 
company to develop this drug for only half of the market, in this case males, when the competing drugs 
are approved for both genders.  
If the outliers (patients who show heterogeneity) account for 1-10% of the population, the 
possibility of studying them is dependent upon resources, and is influenced by the number of groups used 
in the randomization or for the tests of heterogeneity in treatment effects, the percentage of outliers, and 
the use or nonuse of some kind or enrichment strategy for increasing the number of outliers randomized 
into the study. In summary, it is a question of the financial cost and practicality of the RCTs.          
The history of the attempts to explore treatment response heterogeneity in psychiatry 
  Psychiatry has a long history of trying to identify predictors of differential pharmacological 
response but these attempts began before the EBM approach was born, were not developed in the context 
of RCTs and were not tested in RCTs. These attempts came from a different tradition; the mechanistic 
tradition. The developers of these models hypothesized that psychiatric drugs work by modifying specific 
pharmacological mechanisms in the brain. Two of the most important attempts are briefly described: the 
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existence of a serotonergic versus noradrenergic type of depression, and the dexamethasone suppression 
test (DST).  
 The monoamine hypothesis of depression was first formulated in the 1960s71 and some evidence 
that different antidepressants may have differential effects on serotonin and noradrenalin metabolites72 led 
to efforts to classify depressive patients according to pharmacological mechanisms. In that sense, in 1975, 
Maas73 simplistically hypothesized that there are two groups of depressive patients: A (with disorders of 
norepinephrine systems) and B (with disorders of serotonin systems). This approach was described early 
in the first attempts to develop pharmacological guidelines in psychiatry74, before the birth of the EBM 
movement. These guidelines74 were developed by experts using a comprehensive approach including the 
mechanistic and RCT approaches, trying to balance all biological and clinical data and, therefore, giving a 
lot of weight to data beyond those obtained from RCTs.   
 In psychiatry, the DST was the most important biomarker used as a potential index of 
heterogeneity of treatment response. The initial DST research studies in depression in the 1970s75,77 led to 
enthusiasm with which mainstream psychiatry embraced a biological test of the heterogeneity of 
pharmacological response. However, in 1987, a guideline published by The American Psychiatric 
Association (APA) Task Force on Laboratory Tests77 indicated the lack of definitive data of the DST’s 
clinical usefulness in selecting treatment.  In 1988 Nierenberg and Feinstein78 used the history of the 
DST, a diagnostic test initially widely accepted and later rejected, as a cautionary example for avoiding 
similar problems in the future with diagnostic tests. 
These two promising but, in the end, unsuccessful attempts to use biological markers in psychiatry 
are prime examples that the history of addressing heterogeneity in treatment response in psychiatry have 
been rather unproductive. Thus, all recent APA practice guidelines79 incorporate EBM principles but also 
consider clinical consensus. These guidelines address treatment response heterogeneity but they correctly 
point out the limitations of the data. 
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Next steps for moving forward from the current stalemate between EBM and PM  
 This editorial has presented the unsatisfactory status of medical science due to the stalemate 
between EBM and PM and presented a caricatured view of their traditions in order to keep the interest of 
the reader.  
 To move forward, three issues appear important and are described in the next three sections: 1) 
advances in scientific methodology which would bring EBM and PM closer; 2) education of the defenders 
of EBM and PM about the weaknesses of their approaches and the virtues of the other side; and 3) the 
need for openness toward advances in science, in general, that may rescue medicine from this stalemate. 
Many specific solutions are presented in these three sections; unfortunately, many of these ideas are not 
likely to be implemented.  Thus, the discussion of each specific idea is concluded with a comment on its 
limitations. 
Advances in scientific methodology which would bring EBM and PM closer   
Additional development is needed in the following areas:  1) scientific methodologies for PM, 2) 
knowledge of drug-response heterogeneity, 3) introduction of a PM approach to RCTs, and 4) use of a 
PM approach in the development of guidelines for EBM.  
 Development of scientific methodology for PM 
Regarding the  development of methodology for PM, it is important to remember that RCTs are 
usually funded by industry while most of the pharmacogenetic studies using genetic testing to expand PM 
have been conducted by research institutions.80 Two excellent reviews describe some possible types of 
designs for pharmacogenetic studies including RCTs.81,82  As long as no funding sources are identified for 
these studies, this discussion of design types for researching methodological  progress in PM is mostly a 
theoretical exercise.  Grant agencies have traditionally left drug study funding to industry. Pharmaceutical 
companies have no interest in conducting studies once a drug is on the market and especially when it is 
off patent. Companies developing PM tests have very small research budgets when compared with 
pharmaceutical companies.61  In theory, pharmacogenetic studies may help to bring increased use of some 
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of the classic antipsychotic or antidepressant drugs by reducing ADRs83 or may even rescue drugs 
withdrawn from the market.84  In practice, the lack of funding and the enormous cost of any type of study 
that may produce competition with approved drugs on the market and supported by the pharmaceutical 
company marketing is a serious limitation.  
Studying variability between individuals in drug response 
The literature describes three methods for exploring the differences in drug response among 
individuals: 1) pharmacogenetic twin studies, 2) repeated drug studies, and 3) replicate cross-over trials 
after RCTs.  
The typical means of studying genetic versus environmental influences in complex illness has 
been the use of twin studies to compare differences between dizygotic and monozygotic twins. In classic 
formulations monozygotic twins are said to share 100% of their genome while dizygotic twins are said to 
share on average only 50%; in both type of twins, the twin and his/her co-twin were believed to share 
similar levels of environmental influences.85,86 Statistical models have been developed allowing causal 
associations to be made and estimations of heritability to be defined as the proportion of total variance 
that is accounted for by genetic components.85 The assumption of shared environment has always been 
dubious but advances in genetics are beginning to question the genetic assumptions of the twin models 
since monozygotic twins may not share 100% of their genome and they may have differences in CNVs or 
epigenetic changes.86 Thus, twin studies may be a powerful method with high potential for studying some 
aspects of drug response but there are practical limitations since it is not ethical to administer drugs 
prospectively in long-term studies to healthy twins under controlled conditions. The twin model can be 
used for short studies with little risk, particularly using single doses and focusing on pharmacokinetic 
effects. 87 As a matter of fact, recently some twin pharmacological studies have focused on the 
pharmacokinetics of some medications or substances of abuse.85,88,89 Besides these controlled studies, 
“natural experiments” may occur when monozygotic twins take the same drug but show a discordant drug 
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response (e.g., ADRs). In summary, twin studies have some potential to explore the heritability of some 
aspects of drug response and advance scientific knowledge in PM but are limited by practical aspects.85       
Kalow and coworkers42,43 proposed investigating response variation by repeating drug 
administration to the same individuals and comparing the variability of response within and between 
individuals (intra-individual variation versus inter-individual variation). Inter-individual variation in 
response to the same drug may have environmental and/or genetic reasons.  Intra-individual drug 
variation cannot be explained by genetic variations; it can only be explained by instability of measuring 
methods (test-retest reliability), chance, environment or changes in genetic function induced by 
environment (epigenetics).43 For this type of study it is important to use reliable measures, exclude chance 
by using enough relatively large samples, and eliminate known environmental factors that influence drug 
response, including those that may change drug response over time (such as drug tolerance, which is 
probably mediated by epigenetic mechanisms).57 The comparison of intra-individual variation versus 
inter-individual variation provides a measure of heritability. More recently, Kalow’s colleagues90 have:  
1) clarified the types of drugs that can be studied using this method; 2) proposed that a comparison of 
inter- versus intra-subject variability in drug response under minimal environmental exposure may 
provide an upper-bound estimate of heritability of drug efficacy and safety; and 3) indicated that modest 
changes in population averages may underestimate the dramatic impact of a genetic variation at the tails 
of a population. According to Dorne, 91 the effects of polymorphic enzyme outliers may contribute to huge 
differences in metabolism up to a factor of 52 times in CYP2D6 and of 26 times on CYP2C19.     
Senn,41 a statistician, has taken Kalow’s proposal42,43 one step further by proposing the use of what 
he calls replicate cross-over trials.  They are a particular type of cross-over design: those in which the 
same treatment is given to the same subject more than once. A replicate cross-over trial is the equivalent 
of doing ‘n-of-1 trials’ in all the patients included in the RCTs. He also indicated that the data need to be 
analyzed using mixed effects models. This study design is only possible in drugs used for chronic 
illnesses, with reversible effects and no need for long treatments.38 More importantly, it will make RCTs 
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much more expensive. Mant92 opines that it is naïve to think that replicate cross-over trials are a feasible 
solution and that we should resign ourselves to using observational studies to answer questions about 
applicability to individual patients.    
In summary, pharmacogenetic twin studies, repeated drug administration studies, and adding ‘n-
of-1 trials’ after RCTs can be used to establish an upper-bound estimate for individual variations (and 
possibly for heritability) of different aspects for some drug responses, but they have rarely been used and 
have some practical limitations.  Thus, the current status of RCTs is that they can tell us which treatments 
are effective but not necessarily which patient should receive them.93,94 
Personalizing RCTs 
  Predictions based on mechanistic knowledge of genetic or environmental influences on drug 
responses can be incorporated in the design of RCTs. An example would be to stratify patients by genetic 
markers according to our knowledge of pharmacogenetics.  The CYP2D6 gene variations are the best 
understood; one extreme is the poor metabolizer who does not have any CYP2D6 due to lack of 
functional genes and the other extreme is the ultrarapid metabolizer who has too much CYP2D6 enzyme 
due to three or more active genes. Ideally, RCTs stratified by CYP2D6 genotype should be carried out for 
classical antidepressant and antipsychotic drugs that are off-patent but these RCTs will not be supported 
by the industry.  Furthermore, the industry has eliminated CYP2D6 drugs from their pipeline;9 no future 
CYP2D6 drugs will be studied using CYP2D6 knowledge to stratify RCTs.  
Our knowledge of the influence of inhibitors and inducers can also be incorporated in RCTs. The 
industry, however, usually prefers to exclude patients taking inducers or inhibitors from their RCTs and 
ignore the issue completely. A good example of “ignorance” in psychiatry is the failure of risperidone as 
an adjunct treatment in mania compared with placebo when risperidone was added to carbamazepine in a 
RCT.95 A case report,96 case series97,98 and in vitro studies99,100 had demonstrated that carbamazepine is an 
inducer of risperidone metabolism, but the pharmaceutical company’s ignorance of the literature led to a 
partial failure (in the carbamazepine arm) in this RCT.95 To obtain a positive outcome in the 
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carbamazepine arm, the company should have paid attention to this prior mechanistic literature and 
randomized the carbamazepine patients to double the risperidone dose compared with the other manic 
patients taking non-inducers (lithium or valproate). 
Personalizing EBM guidelines  
Guidelines for EBM can be more PM-friendly by: 1) incorporating a more patient-centered 
approach, 2) incorporating a mechanistic pharmacological approach, and 3) rethinking the hierarchy of 
grading recommendations, particularly for drug safety.   
The editors of the family medicine journals101 have proposed that it is possible for guidelines to 
emphasize patient-centered outcomes rather than focus on illness-centered outcomes. Clinical 
pharmacologists and pharmacists have incorporated mechanistic knowledge in the development of 
pharmacogenetic guidelines102-103 and EBM guidelines for diagnostic tests. 105 The approach is different 
than the approach of traditional EBM guidelines since the emphasis is not so much on the availability of 
RCTs to support these recommendations but also incorporates the available mechanistic information in 
the guidelines. Obviously, if one thinks that RCTs is the only way to establish reliable knowledge in 
medicine these types of guidelines incorporating mechanistic knowledge are worthless.   
 Vandenbroucke,106-109 a physician with epidemiological training, has emphasized that the 
hierarchy of innovation in medicine is exactly the opposite of the hierarchy used by EBM in guidelines. 
RCTs are the less innovative and anecdotal findings are the most innovative. More importantly, he 
emphasized that EBM forgets that RCTs were developed to test drug efficacy, not drug safety. As a 
matter of fact, Ioannidis110 proposes that ADRs are “neglected, restricted, distorted, and silenced” in 
RCTs.   According to Vandenbroucke,106-109 RCTs, due to their nature, are limited in detecting ADRs 
since they include:  1) a small number of patients (a few hundred), 2) a limited population (patients with 
comorbidities and poor health are excluded), and 3) a relatively short duration (usually a few months). 
Randomization is not helpful or important for unexpected and unpredictable ADRs. As a matter of fact, 
observational studies (case reports, case series and pharmacoepidemiological studies) have been crucial in 
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establishing new ADR knowledge.109 Thus, strictly from the best scientific methodological point of view, 
EBM’s hierarchy of putting RCTs at the top for drug efficacy may be correct, but for drug safety, RCTs 
may not be particularly helpful. This is demonstrated by the withdrawals from the market of many drugs 
that were proven to be safe in RCTs and were not safe when used in the general population111.  It is also 
demonstrated by an aldosterone RCT that suggested that this drug was associated with decreased 
mortality in advanced congestive heart failure, leading to an EBM guideline and a subsequent increase in 
hospitalizations with no reductions in mortality when aldosterone was used in the general population of 
this type of patient.112  These examples of major problems in extrapolating from the patients studied in 
RCTs to the general population reflects that RCTs may have major problems with external validity.  
Educating EBM and PM defenders regarding their weaknesses and the virtues of the other side  
  It is fitting to be reminded of Reilly’s24 description that EBM is an idealized way of practicing 
medicine.  Four physicians with epidemiological expertise are included in this editorial and the 
accompanying references: Feinstein,1,20,27,33,78 Ioannidis,60,110,114-116 Sackett,10,13,16,21, and Vandenbroucke.5-
7,17,106-109,117 If all physicians were like them, it would be very easy to implement EBM. Unfortunately, we 
(physicians) do not have the superb mathematical minds of these four experts. EBM assumes that 
physicians have the time and knowledge to perform complex computer searches and complete meta-
analyses to resolve their clinical questions. The reality is that completing meta-analyses is not “easy” 
science. A statistician has recently complained that several of the published meta-analyses in top medical 
journals have significant flaws.118    
The writer spends a substantial part of his time helping practicing psychiatrists and psychiatry 
residents with their practical pharmacological problems. This includes considerable effort in teaching 
them to:  1) use PubMed to search for reviews and meta-analyses, and 2) use pharmacokinetic and 
pharmacodynamic knowledge to resolve their questions.  He has had some success in these tasks but he 
has had no success in teaching them basic statistical principles such that they could intelligently assess the 
typical article published in a psychiatric journal. The McMaster University students and physicians may 
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be particularly sophisticated in statistics and epidemiology but the average US practicing physician and 
resident may not be as capable. This is why Feinstein27 insisted that the science of EBM was not 
developed by physician scientists but rather by scientists who were not physicians. A deceptively easy 
solution would be to increase the mathematical training of prospective physicians. In the US, pre-med 
curricula and medical school entrance exams emphasize biology, chemistry, and physics, with little 
emphasis on statistics or mathematical thinking. One can propose substituting the emphasis on physics 
with an emphasis on statistics. Is this likely to happen? No. Is this wise? That is uncertain. The 
psychology of science119 is in its initial stages but there may be a dichotomy of personality traits among 
different individuals according to their career selections. Clinicians tend to be people-oriented and 
scientists tend to be oriented to things.119 Mathematicians, engineers and physicists may have lesser 
people skills than social scientists. It would not be surprising, then, if increasing the mathematical 
requirements for medical students led to different populations of prospective students, with less interest in 
people and fewer social skills.  
The reality is that the application of pharmacological scientific advances is a complex process. In 
the US, where there are few physicians with formal clinical pharmacological training (versus European 
countries that have clinical pharmacology residencies), the mechanistic science of pharmacology is 
mainly developed by pharmacologist scientists and some pharmacists with basic skills; physician 
scientists make minimal contributions. In the area of RCTs some US physician scientists may be the first 
authors of articles but most of the complex statistical designs and analyses are done by biostaticians or 
epidemiologists working for the industry. The meta-analyses of pharmacological studies are usually 
authored by biostaticians or epidemiologists. On the other hand, in the US most of the prescribing is done 
by practicing physicians (or physician extenders) who have very limited pharmacological and statistical 
training. If these practicing clinicians have access to a pharmacist and are wise, they consult the 
pharmacist, who could provide a more comprehensive and mechanistic pharmacological view in treating 
problematic patients. In summary, the author believes that using EBM and conducting meta-analyses for 
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making decisions about drug prescription is an “ideal” way of practicing medicine, but is beyond the 
abilities of current US physicians (and physician extenders).        
 Many of the scientists practicing EBM and writing meta-analyses appear not to understand that 
theories and mechanistic interpretations are a fundamental aspect of medical practice. Any 
pharmacologist knows that selective serotonin reuptake inhibitors (SSRIs) frequently exhibit no linear 
relationship between dosage and plasma concentration, wide ranges between therapeutic and toxic doses, 
and some are powerful self-inhibitors of their metabolism.65 This means that SSRIs are not good 
candidates for CYP genotyping.65 The TCAs are much better candidates for CYP genotyping. However, 
when the epidemiologists from the Agency for Healthcare Research and Quality120,121 decided to examine 
the clinical utility of CYP genotyping in psychiatry, they selected SSRIs instead of TCAs. Not 
surprisingly, the outcome was not good for PM defenders.120,121  Pharmacokinetic knowledge in the CYP 
area would have saved the effort and expense of completing a comprehensive review and a meta-analysis, 
but researchers with an EBM background120,121 did not see the need to review the literature on the 
pharmacokinetic science of SSRIs.    
 Medical science includes epidemiological principles and basic mechanistic science; medical 
practice is the difficult art of taking this knowledge to clinical practice with individual patients. Due to the 
complexity of the task, physicians need to rely on and learn from epidemiologists and basic scientists, 
including pharmacologists. Thus, it is obvious that medicine needs both EBM and PM, and collaboration 
between defenders of EBM and PM is needed to advance medicine. Defenders of each view must 
acknowledge the limitations of their approach, their lack of expertise in the other approach, and that 
collaboration is needed. Tegarden122 used a clinician’s way of thinking by describing a risk-benefit 
analysis to justify the use of warfarin pharmacogenetics in spite of the current lack of available RCTs.   
Advances in science in general that may rescue medicine from this stalemate  
 Three major new advances in science may be relevant for those who think that “outside”  help 
could resolve this stalemate in medicine: 1) the progressive understanding of how science advances, along 
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with its limitations; 2) a new way of scientific thinking called “complexity”; and 3) the initial steps in 
using the scientific approach for defining an expert. 
An interesting advance that is finally being accepted by the experts is that scientific thinking:  1) 
has been very successful but has its weaknesses, 2) has no completely clear demarcations from 
“pseudoscientific” thinking, and 3) is not so different from the thinking used in other sophisticated human 
activities (such as law or the arts).117,123-125 In summary, science is a complex trial-and-error historical 
process led by experts, the scientists.117,123-125 Thus, the influence of subjective and personal issues cannot 
be avoided, to the point that major advances in science can be explained by a complex mix of  1) “charge” 
(discoveries solve problems that are quite obvious but in which the way to solve the problem is not so 
clear), 2) “challenge” (discoveries are explained by a new acknowledgment of the limitations of scientific 
thinking, and  3) “chance” (serendipitous findings made by “prepared minds”).126 Ioannidis,114-116 a 
physician with mathematical training, has conceptualized for medical science the limitations of scientific 
thinking and the difficulties in advancing it. In a series of seminal articles, he has reminded us that the 
majority of published medical findings are false, including many of those obtained through RCTs. 114-115  
He also stated that “important” articles and  “important” journals are not free from the problem of 
spreading false findings; moreover, they are even more prone to it due to the competition to publish 
“significant” findings.115  The “boring  job” of replication,128 the very cornerstone of establishing a 
scientific finding as truth, is discouraged.  Finally, Ioannidis pointed out that significant biases, both 
personal and financial, contribute to the dissemination of false findings.116 In this context, it seems 
important to remind the defenders of the PM and EBM approaches that their fields may not be so different 
in that both are full of false findings; both are biased, but their varying traditions result in different biases.  
Working together and using the strengths of the other side to balance their weaknesses appears wise since, 
according to Naylor116, “clinical medicine seems to consist of a few things we know, a few things we 
think we know (but probably don’t), and lots of things we don’t know at all.”  
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A new current in scientific thinking is called “complexity”130-131, reflecting the complexity of 
scientific exploration and the need for complex computer models. This theory and its accompanying 
computer models are being introduced in medicine, the so-called “network” medicine.132 Network 
analysis may have potential to explore the myriad of genes that might contribute to PM. Two applications 
are briefly discussed here: 1) gene-gene interactions, and 2) ethnicity. When one is sure that a single gene 
has important and definitive effects on response to a specific drug, the task of probing it is “relatively” 
simple; one only needs to establish how all genetic and epigenetic changes modify the activity of the gene 
and determine the clinical relevance of these changes. Therefore, one assumes that this gene has “large 
effect sizes” on the drug’s safety or efficacy so that other genes can be ignored. However, the “elephant in 
the living room” of PM is how to deal with the possibility that myriads of gene-gene interactions are 
likely to be important. The problem of dealing with gene-gene interactions may be mind-boggling if one 
moves from 2 to 3 genes to 20 or 50 genes interacting. Network analyses133, by developing gene 
pathways, may be a reasonable way of dealing with unknown complex gene-gene interactions.  
From the genetic point of view the concepts of race or ethnicity do not make sense, but there are 
obvious genetic differences related to ancestry, due to the evolution of human populations.134 
Unfortunately, what we know about the functionality of genes used in PM (e.g., CYP2D6 and CYP2C19) 
cannot be predicted easily by ancestry markers. Network analysis135 has been used recently to control for 
ancestry but it is not known whether this will be a successful method or not to deal with this complex 
issue.  Badcott136 has argued that putting too much faith in the idea of multiple genes facilitating PM may 
be misleading. The aleatory process of evolution ensures that, with the possible exception of monozygotic 
twins, every human being is genetically unique and that predictive power may be enhanced by knowledge 
and technology, but is ultimately constrained by insuperable probabilistic considerations. It is illusory to 
relate population-level probabilistic causation with individual-level causation.  
Only time will time will tell if these “complexity” and “network” models are a passing fad or a 
contribution to individual patient care through the incorporation of complex information from multiple 
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sources, the final goal of PM. Certainly, it seems hard to convince current practicing physicians that in the 
future specific treatment decisions will be made by ignoring their “subjective” experience and introducing 
hundreds or thousands of pieces of data from genetic or other biomarkers into a computer model that will 
“magically” provide the answer. The word “magically” is used here in the sense that physicians will have 
little clue as to how the software works or was developed.  Another new statistical methodology that may 
be relevant but is even harder to discuss than network analysis, due to its novelty, is the so-called dynamic 
treatment regimens.137 These regimens allow individualization of treatment (type, dosage, timing) of a 
single patient by using a special type of randomized design (called sequential multiple assignment 
randomized trial). Another regimen, a regression-based analysis called Q-learning, may allow exploring 
similar data in non-randomized naturalistic long-term treatment designs. 137 
 An even more “futuristic” scientific development may be science advancement to the point that 
one can study complex human concepts such as “what is an expert.”138 The scientific study of how 
individuals  become experts should be important for both: 1) the defenders of EBM, who believe that 
training with an “expert” was a key tradition in the “art” of medicine, and that EBM is “revolutionary” in 
its attempt to make all physicians more expert and more scientific; and 2) the enemies of EBM, who 
believe that EBM is a part of social process in which the “old” authoritarian structures are hidden behind 
statistical techniques that still need to be interpreted by “experts.” 139,140   
Physicians do not talk about who is an expert but they demonstrate it with their behavior. In a 
simplistic way, in clinical medicine, “experts” are probably those physicians who are consulted on 
difficult cases by other physicians from the same specialty. From the point of view of medical trainees, 
“experts” are those who are more frequently chosen as “mentors” by the young physicians who want to 
learn medicine. In the scientific area, due to large amounts of data available from publications, a more 
“statistical” and “numerical” approach toward determining who is an expert is possible by testing how 
influential the researcher’s articles are. An example of these attempts may be the index “h” developed by 
Hirsch141 to compare, using one number, the most frequently quoted authors in a scientific area. As 
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English is definitively established as the lingua franca for disseminating research and journals from 
countries other than Anglo-Saxon countries have fewer barriers toward being read by researchers, this 
type of index may help to establish the identities of the “current” world experts in a specific area of 
publication. Unfortunately, there is no guarantee that the current medical experts would be the ones 
considered “experts” when the researchers of the next century are looking back. Moreover, history tells us 
that great discoverers are usually ignored by their contemporaries. The scientific approach has not been 
particularly successful in studying and explaining some of the more complex concepts of human life, such 
as expertise and creative spirit, but researchers from different areas including educational sciences are 
trying to define what an “expert” is.138 Even with these advances in understanding what an expert is and 
how to train them, one must hold out the possibility that inherent limitations exist in what science can 
offer for better training experts among physicians. According to Polanyi,125,142 a thinker who began as a 
physician, then became an internationally known chemist and finally a philosopher of science, the process 
of learning medicine with a mentor requires some implicit learning, which is by nature difficult to 
translate into words and is only learned by example.142     
Conclusion 
 Prior articles have described the tension between EBM and PM regarding economic issues143  and 
practical implementation in the clinical environment144-148; one has even proposed that EBM has “been 
effectively sidelined and marginalized” by PM.149  
This editorial focuses on historical and statistical issues that cannot be ignored in understanding 
this tension. The more we believe that PM is needed for one drug, the more this means that drug response 
is not homogeneous and that an unmodified EBM approach will not be helpful. If we decide that EBM is 
the way to go and drug response is homogeneous and well-represented by the mean, we are simply 
ignoring the patients who need personalized prescription. How bad is this? It depends: are we ignoring 
<1%, 10% or 50% of the sample? The pharmaceutical company marketing a drug may feel safe in 
ignoring “a few” outliers. The outlier patients and their families may not be so happy about being ignored. 
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The dilemma entails balancing the public health approach and the individualized approach.8,9  It is easy to 
see why the EBM approach and the personalized prescription approach can be enemies in times of limited 
economic resources and the growth of health expenses due to technological developments.  
The history of using biological markers in psychiatry to address heterogeneity in treatment 
response has been rather unproductive. To move beyond the stalemate between EBM and PM, this 
editorial proposes three types of steps: 1) advancing the scientific methodology to bring EBM and PM 
closer; 2) educating the defenders of EBM and PM about the weaknesses of their approaches and the 
virtues of the other side; and 3) openness to advances in science, in general, that may rescue medicine 
from this stalemate.  
   An armistice between EBM and PM is possible but it will require changing how the various 
interested parties (government agencies, health organizations, health providers and patients) think about 
the complex pharmacological mechanisms of drug responses. It will also require the use of new 
methodological designs for building a PM approach for studying new drugs through the use of 
stratification following mechanistic hypotheses in RCTs and replicate cross-over trails after RCTs. This 
may, however, leave already-marketed drugs with no information on personalization unless funding for 
pharmacogenetic twin studies and repeated drug administration designs is found.  
 “Personalized EBM” 150 is a new term being introduced in the literature.  In the view of the author, 
the development of such an approach can only be based on prescribers gaining a better understanding of 
pharmacological mechanisms,62 as well as a general acknowledgment by all parties (government agencies, 
health organizations, health providers and patients) of the limitations of EBM and PM.  They are both 
complementary and antagonistic in their approaches, such that collaboration between the experts in both 
fields is needed in the advancement of pharmacological science and its applications in the treatment of 
individual patients. 
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Table 1. Statistical assumptions on drug response underlying EBM and PM    _____ 
     EBM    PM      
Statistical homogeneity   Assumed to be present Assumed to be absent  
Statistical heterogeneity  Ignored   Assumed 
Mean     Represents sample well Does not represent sample well 
Outliers    Ignored   Crucial 
Stratification before randomization Not needed   Ideal for studying outliers 
Analyses for HTE   Not needed   Needed if stratification was not done 
HTE: heterogeneity in treatment effects 
 
